image

The best stocks to buy since 1993

Latest issue now available

SIGN UP NOW
Primary Recommendation

Provalis - Expects sale of vaccines business before year end

September 2002

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • PRO
Investors have, understandably, become so nervous about any businesswith a cash burn that they may be missing the investment potential of Provalis. Since January 1999, when the new management teamwas appointed the company can reasonably claim to have done everythinginvestors could have expected. The diagnostic division has taken itsGlycosal G4 test for diabetics from the drawing board to market andacquisitions have been made in the healthcare division to take thispreviously lossmaking part towards profitability. Real profitabilityis now fast approaching in both these divisions. Provalis stillretains a loss-making vaccines R&D business but is expected todispose of it before the year end which should help the shares re ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe

SUBSCRIBE NOW